These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30343116)

  • 1. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.
    Jairath V; Jeyarajah J; Zou G; Parker CE; Olson A; Khanna R; D'Haens GR; Sandborn WJ; Feagan BG
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):63-70. PubMed ID: 30343116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.
    Mohammed Vashist N; Samaan M; Mosli MH; Parker CE; MacDonald JK; Nelson SA; Zou GY; Feagan BG; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011450. PubMed ID: 29338066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2024 Mar; 30(3):370-381. PubMed ID: 37116893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis.
    Narula N; Alshahrani AA; Yuan Y; Reinisch W; Colombel JF
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):411-418.e3. PubMed ID: 29913273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
    Jairath V; Khanna R; Zou GY; Stitt L; Mosli M; Vandervoort MK; D'Haens G; Sandborn WJ; Feagan BG; Levesque BG
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1200-10. PubMed ID: 26388424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.
    Ma C; Jeyarajah J; Guizzetti L; Parker CE; Singh S; Dulai PS; D'Haens GR; Sandborn WJ; Feagan BG; Jairath V
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):447-454.e1. PubMed ID: 33279779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal Ultrasound to Assess Ulcerative Colitis Disease Activity in Children: External Validation and Comparison of 2 Intestinal Ultrasound Activity Indices.
    van Wassenaer EA; van Rijn RR; Zwetsloot SLM; de Voogd FAE; van Schuppen J; Kindermann A; de Meij TGJ; van Limbergen JE; Gecse KB; D'Haens GR; Benninga MA; Koot BGP
    Inflamm Bowel Dis; 2023 Aug; 29(8):1217-1222. PubMed ID: 36149272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
    Jharap B; Sandborn WJ; Reinisch W; D'Haens G; Robinson AM; Wang W; Huang B; Lazar A; Thakkar RB; Colombel JF
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1082-92. PubMed ID: 26381802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis.
    Fluxá D; Simian D; Flores L; Ibáñez P; Lubascher J; Figueroa C; Kronberg U; Pizarro G; Castro M; Piottante A; Vial MT; Quera R
    J Dig Dis; 2017 Nov; 18(11):634-641. PubMed ID: 28949435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis.
    Sagami S; Kobayashi T; Aihara K; Umeda M; Morikubo H; Matsubayashi M; Kiyohara H; Nakano M; Ohbu M; Hibi T
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1373-1383. PubMed ID: 32383166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
    Ma C; Sandborn WJ; D'Haens GR; Zou G; Stitt LW; Singh S; Ananthakrishnan AN; Dulai PS; Khanna R; Jairath V; Feagan BG
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1760-1768.e1. PubMed ID: 31546056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
    Schreiber S; Hanauer SB; Sandborn WJ; Barrett K
    J Crohns Colitis; 2020 Sep; 14(9):1274-1281. PubMed ID: 32179906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.